NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ADMA stock rallies 262.1% in the year-to-date period on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK CITY, NY / ACCESSWIRE / October 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc ("ADMA Biologics" or "the Company") (NASDAQ:ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADMA.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ADMA Biologics, Inc. ("ADMA Biologics, Inc.") (NASDAQ:ADMA) concerning possible violations of federal securities laws. On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.